CTLA4-Ig restores rejection of MHC class-II mismatched allografts by disabling IL-2-expanded regulatory T cells

American Journal of Transplantation

Volumn 12, Issue 9, 2012, Pages 2313-2321

  Charbonnier, L M ^a   Vokaer, B ^a   Lemaitre P H ^a   Field, K A ^b   Leo, O ^a   Le Moine, A ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b BUCKNELL UNIVERSITY   (United States)

Author keywords

Costimulatory blockade; interleukin 2; regulatory T cells; transplantation

Indexed keywords

ABATACEPT; CD28 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; RECOMBINANT INTERLEUKIN 2;

ALLOIMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL EXPANSION; CONTROLLED STUDY; GRAFT REJECTION; GRAFT SURVIVAL; INHIBITION KINETICS; LYMPHOCYTE FUNCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SKIN ALLOGRAFT; TH1 CELL;

ANIMALS; ANTIGENS, CD28; GRAFT REJECTION; HISTOCOMPATIBILITY ANTIGENS CLASS II; HISTOCOMPATIBILITY TESTING; IMMUNOCONJUGATES; INTERLEUKIN-2; MICE; MICE, INBRED C57BL; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY;

EID: 84865598933     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2012.04184.x     Document Type: Article

References (37)

1. Cheng G, Yu A, Malek TR,. T-cell tolerance and the multi-functional role of IL-2R signaling in T-regulatory cells. Immunol Rev 2011; 241: 63-76.
2. Cobbold SP, Adams E, Graca L, et al,. Immune privilege induced by regulatory T cells in transplantation tolerance. Immunol Rev 2006; 213: 239-255. (Pubitemid 44401505)
3. Joffre O, Santolaria T, Calise D, et al,. Prevention of acute and chronic allograft rejection with CD4+CD25+Foxp3+ regulatory T lymphocytes. Nat Med 2008; 14: 88-92.
4. Kendal AR, Chen Y, Regateiro FS, et al,. Sustained suppression by Foxp3+ regulatory T cells is vital for infectious transplantation tolerance. J Exp Med 2011; 208: 2043-2053.
5. Nadig SN, Wieckiewicz J, Wu DC, et al,. In vivo prevention of transplant arteriosclerosis by ex vivo-expanded human regulatory T cells. Nat Med 2010; 16: 809-813.
6. Boyman O, Kovar M, Rubinstein MP, Surh CD, Sprent J,. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 2006; 311: 1924-1927.
7. Koreth J, Matsuoka K, Kim HT, et al,. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med 2011; 365: 2055-2066.
8. Saadoun D, Rosenzwajg M, Joly F, et al,. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med 2011; 365: 2067-2077.
9. Orban T, Bundy B, Becker DJ, et al,. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: A randomised, double-blind, placebo-controlled trial. Lancet 2011; 378: 412-419.
10. Ruderman EM, Pope RM,. Drug Insight: Abatacept for the treatment of rheumatoid arthritis. Nat Clin Pract Rheumatol 2006; 2: 654-660. (Pubitemid 44830854)
11. Vincenti F,. Costimulation blockade in autoimmunity and transplantation. J Allergy Clin Immunol 2008; 121: 299-306. (Pubitemid 351215188)
12. Wojciechowski D, Vincenti F,. Challenges and opportunities in targeting the costimulation pathway in solid organ transplantation. Semin Immunol 2011; 23: 157-164.
13. Grimbert P, Audard V, Diet C, et al,. T-cell phenotype in protocol renal biopsy from transplant recipients treated with belatacept-mediated co-stimulatory blockade. Nephrol Dial Transplant 2011; 26: 1087-1093.
14. Vincenti F, Charpentier B, Vanrenterghem Y, et al,. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10: 535-546.
15. Vincenti F, Larsen C, Durrbach A, et al,. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005; 353: 770-781. (Pubitemid 41215486)
16. Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY,. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 2005; 6: 1142-1151. (Pubitemid 41541792)
17. Vokaer B, Van Rompaey N, Lemaitre PH, et al,. Critical role of regulatory T cells in Th17-mediated minor antigen-disparate rejection. J Immunol 2010; 185: 3417-3425.
18. Webster KE, Walters S, Kohler RE, et al,. In vivo expansion of T reg cells with IL-2-mAb complexes: Induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression. J Exp Med 2009; 206: 751-760.
19. Lu LF, Lind EF, Gondek DC, et al,. Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature 2006; 442: 997-1002. (Pubitemid 44330250)
20. Chougnet CA, Tripathi P, Lages CS, et al,. A major role for Bim in regulatory T cell homeostasis. J Immunol 2011; 186: 156-163.
21. Bour-Jordan H, Salomon BL, Thompson HL, Szot GL, Bernhard MR, Bluestone JA,. Costimulation controls diabetes by altering the balance of pathogenic and regulatory T cells. J Clin Invest 2004; 114: 979-987. (Pubitemid 39578726)
22. Salomon B, Bluestone JA,. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol 2001; 19: 225-252. (Pubitemid 32368035)
23. Salomon B, Lenschow DJ, Rhee L, et al,. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 2000; 12: 431-440.
24. Chen Y, Shen S, Gorentla BK, Gao J, Zhong XP,. Murine regulatory T cells contain hyperproliferative and death-prone subsets with differential ICOS expression. J Immunol 2012; 188: 1698-1707.
25. Coquerelle C, Oldenhove G, Acolty V, et al,. Anti-CTLA-4 treatment induces IL-10-producing ICOS+ regulatory T cells displaying IDO-dependent anti-inflammatory properties in a mouse model of colitis. Gut 2009; 58: 1363-1373.
26. Ito T, Hanabuchi S, Wang YH, et al,. Two functional subsets of FOXP3+ regulatory T cells in human thymus and periphery. Immunity 2008; 28: 870-880.
27. Kornete M, Sgouroudis E, Piccirillo CA,. ICOS-dependent homeostasis and function of Foxp3+ regulatory T cells in islets of nonobese diabetic mice. J Immunol 2012; 188: 1064-1074.
28. Benghiat FS, Graca L, Braun MY, et al,. Critical influence of natural regulatory CD25+ T cells on the fate of allografts in the absence of immunosuppression. Transplantation 2005; 79: 648-654. (Pubitemid 40463170)
29. Li XC, Rothstein DM, Sayegh MH,. Costimulatory pathways in transplantation: Challenges and new developments. Immunol Rev 2009; 229: 271-293.
30. Yang J, Riella LV, Boenisch O, et al,. Paradoxical functions of B7: CD28 costimulation in a MHC class II-mismatched cardiac transplant model. Am J Transplant 2009; 9: 2837-2844.
31. Riella LV, Liu T, Yang J, et al,. Deleterious effect of CTLA4-Ig on a Treg-dependent transplant model. Am J Transplant 2012; 12: 846-855.
32. Wing K, Onishi Y, Prieto-Martin P, et al,. CTLA-4 control over Foxp3+ regulatory T cell function. Science 2008; 322: 271-275.
33. Markees TG, Phillips NE, Gordon EJ, et al,. Long-term survival of skin allografts induced by donor splenocytes and anti-CD154 antibody in thymectomized mice requires CD4(+) T cells, interferon-gamma, and CTLA4. J Clin Invest 1998; 101: 2446-2455. (Pubitemid 28270439)
34. Zheng XX, Markees TG, Hancock WW, et al,. CTLA4 signals are required to optimally induce allograft tolerance with combined donor-specific transfusion and anti-CD154 monoclonal antibody treatment. J Immunol 1999; 162: 4983-4990. (Pubitemid 29314906)
35. Poirier N, Azimzadeh AM, Zhang T, et al,. Inducing CTLA-4-dependent immune regulation by selective CD28 blockade promotes regulatory T cells in organ transplantation. Sci Transl Med 2010; 2: 17ra10.
36. Linsley PS, Nadler SG,. The clinical utility of inhibiting CD28-mediated costimulation. Immunol Rev 2009; 229: 307-321.
37. Herman AE, Freeman GJ, Mathis D, Benoist C,. CD4+CD25+ T regulatory cells dependent on ICOS promote regulation of effector cells in the prediabetic lesion. J Exp Med 2004; 199: 1479-1489. (Pubitemid 38780403)